Treasure Land Development Association

Treasure Land Development Limited is an investment holding company primarily known as the controlling shareholder of Clover Biopharmaceuticals, a global clinical-stage biotechnology company. Through its significant stake in Clover, the entity is involved in the development of novel vaccines and biologic therapeutic candidates for infectious diseases, cancer, and autoimmune disorders. Clover Biopharmaceuticals utilizes its proprietary Trimer-Tag platform to create trimeric fusion proteins that mimic the natural structure of viral proteins. The most notable product associated with this investment is the SCB-2019 COVID-19 vaccine, which has received Emergency Use Authorization in several jurisdictions.